Immunotherapy shows long-term promise in aggressive lymphoma

AI Summary

New five-year clinical trial results demonstrate that the immunotherapy lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, may improve survival for patients with relapsed or refractory large B-cell lymphoma. This therapy offers a promising treatment option for this aggressive blood cancer with poor outcomes under standard care.

A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical trial evaluated lisocabtagene maraleucel (liso-cel), a type of chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), a population with historically limited treatment options and poor outcomes after standard therapies fail.